# EDGAR Filing Document

**Accession Number:** 0001929281
**File Stem:** 0001477932-23-001107
**Filing Date:** 2023-2
**Character Count:** 2871
**Document Hash:** 361d321394f2d932944d583d02e54074
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001107.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0001477932-23-001107

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioLIfe Sciences Inc
- **CENTRAL INDEX KEY:** 0001929281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 542013455
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052
- **BUSINESS PHONE:** 647-470-2278

**MAIL ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052

**BioLife Sciences, Inc.**

**2831 Saint Rose Parkway, Suite 200**

**Henderson, Nevada 89052**

February 17, 2023

<u>VIA EDGAR</u>

Daniel Crawford

Office of Life Sciences

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | BioLife Sciences, Inc. (the "Company") |
|  | Post-qualification Amendment No. 2 to<br> Offering Statement on Form 1-A <br> Filed February 9, 2023 and Post-qualification Amendment No. 3 to Offering Statement on Form 1-A (collectively, the "Post-Qualification Amendment")<br> <u>Commission File No. 024-11898</u> |

---

Dear Mr. Crawford:

On behalf of the Company, I respectfully request that the qualification date of the Post-Qualification Amendment be accelerated and that the Post-Qualification Amendment be declared qualified Friday, February 17, 2023, at 4:00 p.m. EST, or as soon thereafter as is reasonably practicable.

In making this request, the Company represents that the Post-Qualification Amendment will be approved in the State of Colorado, upon qualification by the Securities and Exchange Commission (the "Commission"), and acknowledges the following:

- should the Securities and Exchange Commission (the "Commission") or the Staff, acting pursuant to delegated authority, declare the filing qualified, it does not foreclose the Commission from taking any action with respect to the filing;

- the action of the Commission or the staff, acting pursuant to delegated authority, to declare the filing qualified does not relieve the Company from its full responsibility for the adequacy and accuracy of disclosure in the filing; and

- the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.

---

| |
|:---|
| Very truly yours, |
| */s/ Justin De Four* |
| Justin De Four<br> Chief Executive Officer<br> BioLife Sciences, Inc. |

---